Laman UtamaMOLN • NASDAQ
add
Molecular Partners AG
Tutup sebelumnya
$3.84
Julat hari
$3.84 - $3.95
Julat tahun
$3.36 - $12.70
Permodalan pasaran
155.23J USD
Bilangan Purata
2.89K
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CHF) | Mac 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 16.14J | 259.35% |
Pendapatan bersih | -16.77J | -48.09% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.45 | — |
EBITDA | -15.59J | -2.21% |
Kadar cukai berkesan | 0.01% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CHF) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 130.91J | -24.82% |
Jumlah aset | 141.10J | -23.98% |
Jumlah liabiliti | 12.90J | -24.36% |
Jumlah ekuiti | 128.19J | — |
Syer tertunggak | 37.27J | — |
Harga kepada buku | 1.12 | — |
Pulangan pada aset | -26.94% | — |
Pulangan pada modal | -29.41% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CHF) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -16.77J | -48.09% |
Tunai daripada operasi | -17.08J | -0.18% |
Tunai daripada pelaburan | 34.96J | 98.53% |
Tunai daripada pembiayaan | -302.00K | -0.67% |
Perubahan bersih dalam tunai | 17.50J | 1,588.90% |
Aliran tunai bebas | -13.72J | -22.38% |
Perihal
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Diasaskan
2004
Tapak web
Pekerja
159
